Kim A. Lagerborg

Kim A. Lagerborg

Auto-generated profile, based on publicly available information

Kim A. Lagerborg

Broad Institute of Harvard and MIT, 415 Main Street, Cambridge, MA 02142, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Cell
Verified
Journal Article
Open access
MTMohammadsharif Tabebordbar
Mohammadsharif Tabebordbar
KLKim A. Lagerborg
Kim A. Lagerborg
ASAlexandra Stanton
Alexandra Stanton
EKEmily M. King
Emily M. King
SYSimon Ye
Simon Ye
PSPardis C Sabeti
Pardis C Sabeti
Replacing or editing disease-causing mutations holds great promise for treating many human diseases. Yet, delivering therapeutic genetic modifiers to specific cells in vivo has been challenging, particularly in large, anatomically distributed tissues such as skeletal muscle. Here, we establish an in vivo strategy to evolve and stringently select capsid variants of adeno-associated viruses (AAVs) that enable potent delivery to desired tissues. Using this method, we identify a class of RGD motif-containing capsids that transduces muscle with superior efficiency and selectivity after intravenous injection in mice and non-human primates. We demonstrate substantially enhanced potency and therapeutic efficacy of these engineered vectors compared to naturally-occurring AAV capsids in two mouse models of genetic muscle disease. The top capsid variants from our selection approach show conserved potency for delivery across a variety of inbred mouse strains, and in cynomolgus macaques and human primary myotubes, with transduction dependent on target cell expressed integrin heterodimers.

5 February 2021 in Science
Verified
Journal Article
Open access
PDF file
JLJacob E. Lemieux
Jacob E. Lemieux
KSKatherine Siddle
Katherine Siddle
BSBennett M. Shaw
Bennett M. Shaw
CLChristine Loreth
Christine Loreth
SSStephen Schaffner
Stephen Schaffner
BMBronwyn L. MacInnis
Bronwyn L. MacInnis
Phylogenetics of superspreading: One important characteristic of coronavirus epidemiology is the occurrence of superspreading events. These are marked by a disproportionate number of cases originating from often-times asymptomatic individuals. Using a rich sequence dataset from the early stages of the Boston outbreak, Lemieuxet al.identified superspreading events in specific settings and analyzed them phylogenetically (see the Perspective by Alizon). Using ancestral trait inference, the authors identified several importation events, further investigated the context and contribution of particular superspreading events to the establishment of local and wider SARS-CoV-2 transmission, and used viral phylogenies to describe sustained transmission.Science, this issue p.eabe3261; see also p.574

12 July 2019 in Metabolites
Verified
Journal Article
Open access
PDF file
JAJoseph Antonelli
Joseph Antonelli
BCBrian L. Claggett
Brian L. Claggett
MHMir Henglin
Mir Henglin
AKAndy Kim
Andy Kim
GOGavin Ovsak
Gavin Ovsak
SCSusan Cheng
Susan Cheng
High-throughput metabolomics investigations, when conducted in large human cohorts, represent a potentially powerful tool for elucidating the biochemical diversity underlying human health and disease. Large-scale metabolomics data sources, generated using either targeted or nontargeted platforms, are becoming more common. Appropriate statistical analysis of these complex high-dimensional data will be critical for extracting meaningful results from such large-scale human metabolomics studies. Therefore, we consider the statistical analytical approaches that have been employed in prior human metabolomics studies. Based on the lessons learned and collective experience to date in the field, we offer a step-by-step framework for pursuing statistical analyses of cohort-based human metabolomics data, with a focus on feature selection. We discuss the range of options and approaches that may be employed at each stage of data management, analysis, and interpretation and offer guidance on the analytical decisions that need to be considered over the course of implementing a data analysis workflow. Certain pervasive analytical challenges facing the field warrant ongoing focused research. Addressing these challenges, particularly those related to analyzing human metabolomics data, will allow for more standardization of as well as advances in how research in the field is practiced. In turn, such major analytical advances will lead to substantial improvements in the overall contributions of human metabolomics investigations.

14 December 2021 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
KLKim A. Lagerborg
Kim A. Lagerborg
ENErica Normandin
Erica Normandin
MBMatthew R. Bauer
Matthew R. Bauer
GAGordon Adams
Gordon Adams
KFKatherine Figueroa
Katherine Figueroa
KSKatherine J. Siddle
Katherine J. Siddle

27 October 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
ODOlga Demler
Olga Demler
YLYanyan Liu
Yanyan Liu
HLHeike Luttmann-Gibson
Heike Luttmann-Gibson
JWJeramie D. Watrous
Jeramie D. Watrous
KLKim A. Lagerborg
Kim A. Lagerborg
SMSamia Mora
Samia Mora
Omega-3 (n-3) treatment may lower cardiovascular risk, yet its effects on the circulating lipidome and relation to cardiovascular risk biomarkers are unclear. We hypothesized that n-3 treatment is associated with favorable changes in downstream fatty acids (FAs), oxylipins, bioactive lipids, clinical lipid and inflammatory biomarkers. We examined these VITAL200, a nested substudy of 200 subjects balanced on demographics and treatment and randomly selected from the Vitamin D and Omega-3 Trial (VITAL). VITAL is a randomized double-blind trial of 840 mg/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) vs. placebo among 25,871 individuals. Small polar bioactive lipid features, oxylipins and FAs from plasma and red blood cells were measured using three independent assaying techniques at baseline and one year. The Women’s Health Study (WHS) was used for replication with dietary n-3 intake. Randomized n-3 treatment led to changes in 143 FAs, oxylipins and bioactive lipids (False Discovery Rate (FDR) < 0.05 in VITAL200, validated (p-values < 0.05)) in WHS with increases in 95 including EPA, DHA, n-3 docosapentaenoic acid (DPA-n3), and decreases in 48 including DPA-n6, dihomo gamma linolenic (DGLA), adrenic and arachidonic acids. N-3 related changes in the bioactive lipidome were heterogeneously associated with changes in clinical lipid and inflammatory biomarkers. N-3 treatment significantly modulates the bioactive lipidome, which may contribute to its clinical benefits.

6 October 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
Joonatan PalmuJoonatan Palmu
Joonatan Palmu
JWJeramie D. Watrous
Jeramie D. Watrous
KMKysha Mercader
Kysha Mercader
AHAki S. Havulinna
Aki S. Havulinna
KLKim A. Lagerborg
Kim A. Lagerborg
TNTeemu Niiranen
Teemu Niiranen
Background: Epidemiological and animal studies have associated systemic inflammation with blood pressure (BP). However, the mechanistic factors linking inflammation and BP remain unknown. Fatty acid–derived eicosanoids serve as mediators of inflammation and have been suggested to regulate renal vascular tone, peripheral resistance, renin‐angiotensin system, and endothelial function. We hypothesize that specific proinflammatory and anti‐inflammatory eicosanoids are linked with BP. Methods and Results: We studied a population sample of 8099 FINRISK 2002 participants randomly drawn from the Finnish population register (53% women; mean age, 48±13 years) and, for external validation, a sample of 2859 FHS (Framingham Heart Study) Offspring study participants (55% women; mean age, 66±9 years). Using nontargeted liquid chromatography–mass spectrometry, we profiled 545 distinct high‐quality eicosanoids and related oxylipin mediators in plasma. Adjusting for conventional hypertension risk factors, we observed 187 (34%) metabolites that were significantly associated with systolic BP ( P <Bonferroni‐corrected threshold of 0.05/545). We used forward selection linear regression modeling in FINRISK to define a general formula for individual eicosanoid risk score. Individuals of the top risk score quartile in FINRISK had a 9.0 (95% CI, 8.0–10.1) mm Hg higher systolic BP compared with individuals in the lowest quartile in fully adjusted models. Observed metabolite associations were consistent across FINRISK and FHS. Conclusions: Plasma eicosanoids demonstrate strong associations with BP in the general population. As eicosanoid compounds affect numerous physiological processes that are central to BP regulation, they may offer new insights about the pathogenesis of hypertension, as well as serve as potential targets for therapeutic intervention.